Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

41 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase IIa Global Study Evaluating Rituximab for the Treatment of Pediatric Patients With Granulomatosis With Polyangiitis or Microscopic Polyangiitis.
Brogan P, Yeung RSM, Cleary G, Rangaraj S, Kasapcopur O, Hersh AO, Li S, Paripovic D, Schikler K, Zeft A, Bracaglia C, Eleftheriou D, Pordeli P, Melega S, Jamois C, Gaudreault J, Michalska M, Brunetta P, Cooper JC, Lehane PB; PePRS Study Group. Brogan P, et al. Among authors: brunetta p. Arthritis Rheumatol. 2022 Jan;74(1):124-133. doi: 10.1002/art.41901. Epub 2021 Dec 5. Arthritis Rheumatol. 2022. PMID: 34164952 Free PMC article. Clinical Trial.
Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial.
Merrill JT, Neuwelt CM, Wallace DJ, Shanahan JC, Latinis KM, Oates JC, Utset TO, Gordon C, Isenberg DA, Hsieh HJ, Zhang D, Brunetta PG. Merrill JT, et al. Arthritis Rheum. 2010 Jan;62(1):222-33. doi: 10.1002/art.27233. Arthritis Rheum. 2010. PMID: 20039413 Free PMC article. Clinical Trial.
Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study.
Rovin BH, Furie R, Latinis K, Looney RJ, Fervenza FC, Sanchez-Guerrero J, Maciuca R, Zhang D, Garg JP, Brunetta P, Appel G; LUNAR Investigator Group. Rovin BH, et al. Among authors: brunetta p. Arthritis Rheum. 2012 Apr;64(4):1215-26. doi: 10.1002/art.34359. Epub 2012 Jan 9. Arthritis Rheum. 2012. PMID: 22231479 Free article. Clinical Trial.
Rituximab for the treatment of relapses in antineutrophil cytoplasmic antibody-associated vasculitis.
Miloslavsky EM, Specks U, Merkel PA, Seo P, Spiera R, Langford CA, Hoffman GS, Kallenberg CG, St Clair EW, Tchao NK, Viviano L, Ding L, Iklé D, Villarreal M, Jepson B, Brunetta P, Allen NB, Fervenza FC, Geetha D, Keogh K, Kissin EY, Monach PA, Peikert T, Stegeman C, Ytterberg SR, Stone JH; Rituximab in ANCA-Associated Vasculitis-Immune Tolerance Network Research Group. Miloslavsky EM, et al. Among authors: brunetta p. Arthritis Rheumatol. 2014 Nov;66(11):3151-9. doi: 10.1002/art.38788. Arthritis Rheumatol. 2014. PMID: 25047592 Free PMC article. Clinical Trial.
Outcomes of nonsevere relapses in antineutrophil cytoplasmic antibody-associated vasculitis treated with glucocorticoids.
Miloslavsky EM, Specks U, Merkel PA, Seo P, Spiera R, Langford CA, Hoffman GS, Kallenberg CG, St Clair EW, Tchao NK, Ding L, Iklé D, Villareal M, Lim N, Brunetta P, Fervenza FC, Monach PA, Stone JH; Rituximab in ANCA-Associated Vasculitis-Immune Tolerance Network Research Group. Miloslavsky EM, et al. Among authors: brunetta p. Arthritis Rheumatol. 2015 Jun;67(6):1629-36. doi: 10.1002/art.39104. Arthritis Rheumatol. 2015. PMID: 25776953 Free PMC article. Clinical Trial.
The Pharmacogenomic Association of Fcγ Receptors and Cytochrome P450 Enzymes With Response to Rituximab or Cyclophosphamide Treatment in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.
Cartin-Ceba R, Indrakanti D, Specks U, Stone JH, Hoffman GS, Kallenberg CG, Langford CA, Merkel PA, Spiera RF, Monach PA, St Clair EW, Seo P, Tchao NK, Ytterberg SR, Brunetta PG, Song H, Birmingham D, Rovin BH; RAVE-Immune Tolerance Network Research Group. Cartin-Ceba R, et al. Among authors: brunetta pg. Arthritis Rheumatol. 2017 Jan;69(1):169-175. doi: 10.1002/art.39822. Arthritis Rheumatol. 2017. PMID: 27482943
Effect of Disease Activity, Glucocorticoid Exposure, and Rituximab on Body Composition During Induction Treatment of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.
Wallace ZS, Miloslavsky EM, Cascino M, Unizony SH, Lu N, Hoffman GS, Kallenberg CGM, Langford CA, Merkel PA, Monach PA, Seo P, Spiera R, St Clair EW, Specks U, Brunetta P, Choi HK, Stone JH. Wallace ZS, et al. Among authors: brunetta p. Arthritis Care Res (Hoboken). 2017 Jul;69(7):1004-1010. doi: 10.1002/acr.23099. Arthritis Care Res (Hoboken). 2017. PMID: 27696762 Free PMC article. Clinical Trial.
Pharmacokinetics of rituximab and clinical outcomes in patients with anti-neutrophil cytoplasmic antibody associated vasculitis.
Cornec D, Kabat BF, Mills JR, Cheu M, Hummel AM, Schroeder DR, Cascino MD, Brunetta P, Murray DL, Snyder MR, Fervenza F, Hoffman GS, Kallenberg CGM, Langford CA, Merkel PA, Monach PA, Seo P, Spiera RF, St Clair EW, Stone JH, Barnidge DR, Specks U. Cornec D, et al. Among authors: brunetta p. Rheumatology (Oxford). 2018 Apr 1;57(4):639-650. doi: 10.1093/rheumatology/kex484. Rheumatology (Oxford). 2018. PMID: 29340623 Free PMC article. Clinical Trial.
41 results